Normal cells undergo a variety of genetic/epigenetic alterations which can be summarized in vitro by two major phenotypic changes: immortalization and transformation. Normal cells need to HhAntag691 clinical trial overcome cell cycle checkpoints and their limited division potential to achieve immortalization. Interlaced with this process, additional events contribute to cellular transformation and move cells toward the complete neoplastic phenotype. Human lung and colon cancers, genetically altered mice, mouse and human cell culture models, have all been extensively used to support the multistep progression model. Normal human epithelial or fibroblast cell transformation can be obtained with the sequential expression of a series of oncogenes, often including the viral proteins SV40LT or adenovirus early protein E1A. Some E1A domains conserved in SV40LT, including the CR1/CR2 Rb family binding domains and the p300/400-binding pocket are absolutely required for this transformation process. Despite the importance of these domains, the characterization of other viral oncogenic domains involved in transformation remains incomplete and additional activities could contribute to the carcinogenesis process. Polyomavirus, an oncogenic member of the papovaviruses, causes tumors in rodents and transforms primary cells in culture. In Py-Ibrutinib induced carcinogenesis, Large-T antigen is responsible for inappropriate cell cycle promotion and immortalization of mouse primary cells in culture. This ability is mediated principally through the binding and inactivation of pRb’s by the CR1/CR2 amino-terminal domains. PyLT genetically and functionally shares extensive homology 
with the closely related SV40LT, although critical differences exist. As an example, while both proteins can bind p300 and inactivate the pRb family of tumor suppressors, only SV40LT can bind and inactivate p53. Functionally, SV40LT is a dual oncogene able to immortalize and transform primary rodent cells as a single event while PyLT appears limited to immortalization in vitro. Thus, differences between PyLT and SV40LT render these LT-Ags useful in studying different aspects of oncogenesis. Congruent with its in vitro activity, PyLT drives tumor formation when expressed under various promoters in transgenic mouse models, but the lower frequency and longer latency suggest a requirement for additional secondary events. While PyLT alone cannot transform cells in culture, it can confer resistance to growth arrest in low serum condition and protect cells against Fas and TNF-a induced apoptosis. This ability to evade apoptotic signals could potentially promote growth and allow cells to evade cellular-mediated immunity; important events in multistep carcinogenesis. Moreover, while PyLT does not bind p53 directly, it has the ability to overcome some effects of this master tumor suppressor, notably p53-induced cell cycle arrest. Finally, all E1A domains known to be essential to human cell transformation are not only conserved in SV40LT but are also found in PyLT. Based on this evidence, we hypothesized that, in addition to its immortalizing activity, PyLT also modulates important functions in early mouse cell transformation. Here, we present a strategy where PyLT induced immortalization-independent events can be revealed using NIH3T3 immortal mouse embryonic fibroblasts which already harbor immortalization-associated events that have occurred prior to PyLT introduction. Using gene expression microarray analysis, we identified Necdin among a set of genes that were consistently upregulated following PyLT expression in NIH3T3 cells. Necdin was first identified as a neuronal differentiation marker associated with growth arrest, but has since been found in several normal tissues.